+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H1 2019

  • ID: 4769181
  • Drug Pipelines
  • Region: New York
  • 58 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Kymera Therapeutics LLC
  • Nyrada Inc
  • Rigel Pharmaceuticals Inc
  • MORE
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H1 2019

Summary

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 18 molecules. The latest report Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2019, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10 and 3 respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Infectious Disease and Women's Health which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Psoriasis, Autoimmune Disorders, Gouty Arthritis (Gout), Inflammation, Arthritis, Chronic Kidney Disease (Chronic Renal Failure), Endometriosis, Lupus Erythematosus, Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Pelvic Inflammatory Disease (Pelvic Infections), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
  • The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Kymera Therapeutics LLC
  • Nyrada Inc
  • Rigel Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Amgen Inc

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Bayer AG

Beijing Hanmi Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Genentech Inc

Kymera Therapeutics LLC

Merck & Co Inc

Nyrada Inc

Pfizer Inc

Rigel Pharmaceuticals Inc

TG Therapeutics Inc

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles

AS-2444697 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1830839 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1834845 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-4948 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KYM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-346 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06650833 MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-835 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IRAK-4 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IRAK4 for B-Cell Lymphoma and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IRAK4 for Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Apr 08, 2019: Curis announces advancement to the 200mg BID cohort in the CA-4948 study

Mar 29, 2019: Kymera Therapeutics to present new preclinical data for its first-in-class oral IRAK4 degrader in MYD88-mutant lymphoma at late-breaking session of the American Association for Cancer Research Annual Meeting

Jan 07, 2019: Rigel Pharmaceuticals provides business update on its investigational drug R835

Dec 03, 2018: Kymera Therapeutics presents first validation of IRAK4 protein degraders in MYD88-mutant lymphoma

Nov 20, 2018: Curis to present at the 60th annual meeting of the American Society of Hematology

Sep 25, 2018: Noxopharm finds new approach to address chronic inflammation

Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

Jan 17, 2018: Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma

Mar 30, 2017: Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-4948 at AACR Annual Meeting

Nov 08, 2015: Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule IRAK4 Program at AACR-NCI-EORTC International Conference

Apr 20, 2015: TG Therapeutics Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting

Apr 18, 2015: Aurigene to Present its IRAK-4 Inhibitors Programs at AACR 2015

Apr 14, 2015: Curis Announces Presentation of Data From IRAK-4 Program at AACR Annual Meeting

Nov 12, 2012: Nimbus discovery presents preclinical data on highly selective IRAK4 inhibitors for the treatment of rheumatic diseases.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Amgen Inc, H1 2019

Pipeline by Astellas Pharma Inc, H1 2019

Pipeline by AstraZeneca Plc, H1 2019

Pipeline by Aurigene Discovery Technologies Ltd, H1 2019

Pipeline by Bayer AG, H1 2019

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2019

Pipeline by Bristol-Myers Squibb Co, H1 2019

Pipeline by Genentech Inc, H1 2019

Pipeline by Kymera Therapeutics LLC, H1 2019

Pipeline by Merck & Co Inc, H1 2019

Pipeline by Nyrada Inc, H1 2019

Pipeline by Pfizer Inc, H1 2019

Pipeline by Rigel Pharmaceuticals Inc, H1 2019

Pipeline by TG Therapeutics Inc, H1 2019

Dormant Projects, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Bayer AG
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Bristol-Myers Squibb Co
  • Genentech Inc
  • Kymera Therapeutics LLC
  • Merck & Co Inc
  • Nyrada Inc
  • Pfizer Inc
  • Rigel Pharmaceuticals Inc
  • TG Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll